When was Dicerna Pharmaceuticals founded?

Dicerna Pharmaceuticals was founded in 2007 and raised its 1st funding round 1 year after it was founded.

Where is Dicerna Pharmaceuticals located?

Dicerna Pharmaceuticals is headquartered in Lexington, United States.

Who is the current CEO of Dicerna Pharmaceuticals?

Douglas Fambrough of Dicerna Pharmaceuticals.

How many employees does Dicerna Pharmaceuticals have?

As of Mar 31, 2026, the latest employee count at Dicerna Pharmaceuticals is 73.

Is Dicerna Pharmaceuticals a funded company?

Dicerna Pharmaceuticals is a funded company, having raised a total of $106M across 7 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jul 15, 2008.

How much is Dicerna Pharmaceuticals worth?

The last known valuation of Dicerna Pharmaceuticals was $***** as of Nov 18, 2021.

When was the latest funding round of Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals' latest funding was a $***** Post IPO round on Dec 19, 2018, with participation from 1 investor. Its primary sector is Gene Therapy. In United States, the Gene Therapy sector has seen $1.16B in funding in 2026 to date.

What is the annual revenue of Dicerna Pharmaceuticals?

Annual revenue of Dicerna Pharmaceuticals is between $100M and $500M as on Dec 31, 2020

Where does Dicerna Pharmaceuticals rank among its competitors?

Dicerna Pharmaceuticals ranks 34th amongst 459 active competitors, of which 156 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was City Therapeutics, which secured $99.5M in Jun, 2026.

Who are the top competitors of Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals' top competitors include Alnylam, Nanopore Technologies and MedGenome. Among them, City Therapeutics secured the most recent funding round in June, 2026.

Dicerna Pharmaceuticals - 2026 Company Profile, Team, Funding, Competitors & Financials

Dicerna Pharmaceuticals is an acquired company based in Lexington (United States), founded in 2007 by Douglas Fambrough. It operates as a Developer of drugs by using RNA interference technology platform. Dicerna Pharmaceuticals has raised $106M in funding from Domain Associates and RA Capital Management, with last known valuation of $*****. The company has 459 active competitors, including 156 funded and 108 that have exited. Its top competitors include companies like Alnylam, Nanopore Technologies and MedGenome.

Company Details

Developer of drugs by using RNA interference technology platform. The company's lead product includes RNA which is used for the treatment of hepatocellular carcinoma. Others include drugs for primary hyperoxaluria, genetic liver disease, cardiovascular disease, and hepatitis B virus among others. The GalXC technology is used to create therapies that silence disease-causing genes.

Website: dicerna.com
Social
Email ID: *****@dicerna.com
Phone Number: +1 **********

Key Metrics

Founded Year

2007

Location

Lexington, United States

Stage

Acquired

Total Funding

$106M in 7 rounds

Latest Funding Round

Post IPO, Dec 19, 2018, $*****

Last Known Valuation

$***** as on Nov 18, 2021

Investors

Domain Associates & 19 more

Ranked

34^th among 459 active competitors

Annual Revenue

$100M - $500M as on Dec 31, 2020

Employee Count

73 as on Mar 31, 2026

Similar Companies

Alnylam & 602 more

Exit Details

Acquired by New Nordic (Nov 18, 2021)

View Dicerna Pharmaceuticals' full profile

Dicerna Pharmaceuticals is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
DICERNA PHARMACEUTICALS INC CIN: 1399529 , United States, Active	Oct 23, 2006	$100M - $500M (As on Dec 31, 2020)	337 (As on Dec 31, 2021)	-

Dicerna Pharmaceuticals got acquired by New Nordic on Nov 18, 2021 at an acquisition amount of $*****.

Click here to take a look at Dicerna Pharmaceuticals's acquisition in detail

Dicerna Pharmaceuticals has raised a total funding of $106M over 7 rounds. Its first funding round was on Jul 15, 2008. Its latest funding round was a Post IPO round on Dec 19, 2018 for $*****. 1 investor participated in its latest round. Dicerna Pharmaceuticals has 20 institutional investors.

Here is the list of recent funding rounds of Dicerna Pharmaceuticals:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 19, 2018	4141741	Post IPO	7676007	1814203	3043389	9588146
Mar 30, 2017	8642936	Post IPO	8906661	3905334	2077343	EcoR1 & 5 more
Aug 13, 2013	3558124	Series C	2383354	1787777	RA Capital Management	Abingworth & 9 more

Access funding benchmarks and valuations. Sign up today!

View details of Dicerna Pharmaceuticals's funding rounds and investors

The founders of Dicerna Pharmaceuticals is Douglas Fambrough.

Here are the details of Dicerna Pharmaceuticals' key team members:

Douglas Fambrough: Founder & CEO of Dicerna Pharmaceuticals.

View details of Dicerna Pharmaceuticals's Founder profiles and Board Members

Dicerna Pharmaceuticals' employee count trend

Dicerna Pharmaceuticals has 73 employees as of Mar 26. Here is Dicerna Pharmaceuticals's employee count trend over the years:

Employee count trend for Dicerna Pharmaceuticals

Uncover Dicerna Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Dicerna Pharmaceuticals include Alnylam, Nanopore Technologies and MedGenome. Here is the list of Top 10 competitors of Dicerna Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 14 others	81/100
2nd	Nanopore Technologies 2005, Oxford (United Kingdom), Public	Manufacturer of portable and benchtop devices for real-time DNA sequencing	$1.34B	IP Group, GIC & 95 others	76/100
3rd	MedGenome 2013, Bengaluru (India), Series E	Provider of DNA sequencing, bioinformatics, and multiomics services	$264M	Novo Holdings, Peak XV Partners & 30 others	70/100
4th	Geneoscopy 2015, St. Louis (United States), Series C	Developer of non-invasive biomarker tests for colorectal cancer	$219M	LightChain Capital, Cultivation Capital & 18 others	69/100
5th	City Therapeutics 2006, Cambridge (United States), Public	Developer of gene therapies for multiple diseases	$234M	Arch Venture Partners, Sofinnova Investments ... & 9 others	68/100
6th	Intellia Therapeutics 2014, Cambridge (United States), Public	Developer of genome editing therapeutics using CRISPR and Cas9 technology	$85M	Atlas Venture, Novartis & 10 others	68/100
7th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Coatue & 19 others	67/100
8th	Arrowhead Pharmaceuticals 1989, Pasadena (United States), Acquired	Developer of therapeutics to treat multiple diseases	$60M	Colt Ventures, RTW Investments & 8 others	64/100
9th	Deep Genomics 2014, Toronto (Canada), Series C	AI-powered platform for RNA biology to accelerate genetic therapy discovery	$238M	SoftBank Vision Fund, True Ventures & 16 others	64/100
10th	UniQure 1998, Amsterdam (Netherlands), Public	Developer of gene-based therapies for patients with genetic or acquired diseases	$111M	Gilde Healthcare, Advent Life Sciences & 11 others	63/100
34th	Dicerna Pharmaceuticals 2007, Lexington (United States), Acquired	Developer of drugs by using RNA interference technology platform	$106M	Access Industries, Bain Capital Life Sciences ... & 18 others	57/100